Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Extension Study of the Safety and Tolerability of CORLUX™ (Mifepristone) for Recurrent Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features

NCT00208156 is registered in ClinicalTrials.gov with Corcept Therapeutics as lead sponsor.

NCT NCT00208156
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00208156 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Extension Study of the Safety and Tolerability of CORLUX™ (Mifepristone) for Recurrent Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features
Lead sponsor
Corcept Therapeutics
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2005
Completion date
November 30, 2006
Enrollment
87 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

depressive disorder, major